Find a Doctor

GH
Areas of Expertise

Gerd Horneff

German Society Of Rheumatology
Male

Bio

He has been an author on 171 peer reviewed articles and participated in 6 clinical trials in the past 15 years.

Areas of Expertise

Contact

DE

Latest Advances

Latest Advance
Study
  • Condition: Juvenile Idiopathic Arthritis
  • Journal: Arthritis research & therapy
  • Treatment Used: Etanercept
  • Number of Patients: 2725
  • Published —
In this study, researchers evaluated the long-term safety and effectiveness of etanercept for the treatment of juvenile idiopathic arthritis.
Latest Advance
Study
  • Condition: Juvenile Idiopathic Arthritis
  • Journal: Expert opinion on drug safety
  • Treatment Used: Biologicals
  • Number of Patients: 0
  • Published —
This review summarized safety concerns of the treatment of juvenile idiopathic (of unknown cause) arthritis with various biologics.
Latest Advance
Study
  • Condition: Cryopyrin-associated Periodic Syndrome
  • Journal: Arthritis & rheumatology (Hoboken, N.J.)
  • Treatment Used: canakinumab
  • Number of Patients: 17
  • Published —
The purpose of the study was to assess the long-term efficacy and safety of canakinumab and the response to vaccination in children ages less than 5 with cryopyrin-associated periodic syndrome.
Latest Advance
Study
  • Condition: Oligoarticular Arthritis in Children
  • Journal: Arthritis research & therapy
  • Treatment Used: Etanercept
  • Number of Patients: 109
  • Published —
In this study, researchers evaluated the outcomes of long-term use of etanercept for the treatment of oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis in children
Latest Advance
Study
  • Condition: Uveitis Associated with Juvenile Idiopathic Arthritis (JIAU)
  • Journal: Seminars in arthritis and rheumatism
  • Treatment Used: Anti-Inflammatory Treatment
  • Number of Patients: 0
  • Published —
This article updated the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis (JIAU).
Latest Advance
Study
  • Condition: Juvenile idiopathic arthritis (JIA)
  • Journal: Scandinavian journal of rheumatology
  • Treatment Used: Adalimumab, adalimumab and methotrexate
  • Number of Patients: 584
  • Published —
This study is aimed at exploring the response treatment of incorporating methotrexate to the already used chemotherapy approach with adalimumab for patients with Juvenile idiopathic arthritis (JIA).
Latest Advance
Study
  • Condition: Systemic Juvenile Idiopathic Arthritis (JIA)
  • Journal: Annals of the rheumatic diseases
  • Treatment Used: Canakinumab
  • Number of Patients: 144
  • Published —
This study evaluated the long-term effectiveness and safety of canakinumab in patients with active systemic juvenile idiopathic (of unknown cause) arthritis (JIA).
Latest Advance
Study
  • Condition: Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-related Arthritis, Psoriasis, And Crohn's Disease
  • Journal: The Journal of pediatrics
  • Treatment Used: Adalimumab
  • Number of Patients: 577
  • Published —
The purpose of the study was to evaluate the safety of adalimumab in pediatric patients with juvenile idiopathic arthritis, psoriasis and crohn's disease.
Latest Advance
Study
  • Condition: Juvenile Idiopathic Arthritis (JIA)
  • Journal: Arthritis care & research
  • Treatment Used: Biologic Disease-Modifying Antirheumatic Drug (bDMARD)
  • Number of Patients: 701
  • Published —
This study evaluated juvenile idiopathic arthritis (JIA) long-term outcomes in relation to the time of initiation of biologic disease-modifying antirheumatic drug (bDMARD).

Clinical Trials

Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 100
  • Start Date: January 12, 2021
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 103
  • Start Date: February 12, 2020
Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Combination Product
  • Participants: 30
  • Start Date: November 28, 2019
A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 40
  • Start Date: October 16, 2019
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 190
  • Start Date: April 5, 2019
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 197
  • Start Date: December 17, 2018
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)

All Publications
View All

Publication
Conference
  • Sponsor: American College of Rheumatology (ACR)
  • Event Name: American College of Rheumatology Annual Scientific Meeting 2020
  • Published —
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Publication
Conference
  • Sponsor: American College of Rheumatology (ACR)
  • Event Name: American College of Rheumatology Annual Scientific Meeting 2020
  • Published —
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry

Contact

DE

Insurance

Contact them to find out if they accept your insurance plan.